# Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease

> **NCT03762824** · PHASE4 · COMPLETED · sponsor: **Region Skane** · enrollment: 300 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Systemic Lupus
- Sjögren Syndrome
- Systemic Vasculitis
- Spondyloarthritis

## Interventions

- **BIOLOGICAL:** 13-valent pneumococcal conjugate vaccine
- **BIOLOGICAL:** 23-valent pneumococcal polysaccharide vaccine

## Key facts

- **NCT ID:** NCT03762824
- **Lead sponsor:** Region Skane
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-14
- **Primary completion:** 2018-09-03
- **Final completion:** 2020-12-21
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03762824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03762824, "Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03762824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*